• BioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress

    Source: Nasdaq GlobeNewswire / 27 Jul 2016 11:30:15   America/Los_Angeles

    N/A
Share on,